Free Trial

Pluri (PLUR) Competitors

Pluri logo
$4.10 -0.15 (-3.53%)
Closing price 03:47 PM Eastern
Extended Trading
$4.10 0.00 (0.00%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLUR vs. CTOR, CCCC, GLSI, MOLN, ANIX, ABOS, BTMD, TVGN, ZYBT, and TIL

Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Citius Oncology (CTOR), C4 Therapeutics (CCCC), Greenwich LifeSciences (GLSI), Molecular Partners (MOLN), Anixa Biosciences (ANIX), Acumen Pharmaceuticals (ABOS), biote (BTMD), Tevogen Bio (TVGN), Zhengye Biotechnology (ZYBT), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry.

Pluri vs. Its Competitors

Pluri (NASDAQ:PLUR) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Pluri has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Citius Oncology has a beta of 2.92, indicating that its share price is 192% more volatile than the S&P 500.

Citius Oncology has lower revenue, but higher earnings than Pluri.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluri$1.34M24.97-$22.58M-$5.17-0.79
Citius OncologyN/AN/AN/AN/AN/A

16.6% of Pluri shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 25.9% of Pluri shares are held by company insiders. Comparatively, 6.7% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Citius Oncology had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Citius Oncology and 1 mentions for Pluri. Pluri's average media sentiment score of 1.84 beat Citius Oncology's score of 0.00 indicating that Pluri is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pluri
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Citius Oncology
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pluri presently has a consensus price target of $12.00, suggesting a potential upside of 192.68%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 235.20%. Given Citius Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology is more favorable than Pluri.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluri
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Citius Oncology
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Citius Oncology has a net margin of 0.00% compared to Pluri's net margin of -1,701.19%. Citius Oncology's return on equity of -51.93% beat Pluri's return on equity.

Company Net Margins Return on Equity Return on Assets
Pluri-1,701.19% -4,191.91% -88.27%
Citius Oncology N/A -51.93%-22.17%

Summary

Citius Oncology beats Pluri on 9 of the 12 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLUR vs. The Competition

MetricPluriMED IndustryMedical SectorNASDAQ Exchange
Market Cap$34.66M$3.48B$6.17B$10.68B
Dividend YieldN/A2.27%5.70%4.84%
P/E Ratio-0.7923.3929.4727.36
Price / Sales24.97485.50589.24132.03
Price / CashN/A45.2825.8230.35
Price / Book-37.2710.6112.526.69
Net Income-$22.58M-$52.56M$3.32B$276.59M
7 Day Performance-8.48%4.94%2.43%0.97%
1 Month Performance-14.49%16.10%8.78%3.95%
1 Year Performance-13.68%14.51%62.11%36.40%

Pluri Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLUR
Pluri
2.4477 of 5 stars
$4.10
-3.5%
$12.00
+192.7%
-10.6%$34.66M$1.34M-0.79150Positive News
CTOR
Citius Oncology
2.0751 of 5 stars
$1.76
+1.5%
$6.00
+241.7%
+37.1%$146.65MN/A0.00N/AGap Up
CCCC
C4 Therapeutics
3.5829 of 5 stars
$2.03
-4.0%
$8.50
+319.8%
-62.7%$145.54M$35.58M-1.29150Gap Up
GLSI
Greenwich LifeSciences
1.2498 of 5 stars
$10.45
+1.5%
$42.00
+301.9%
-29.9%$143.81MN/A-7.763
MOLN
Molecular Partners
1.4962 of 5 stars
$3.56
-6.2%
$8.00
+125.0%
-22.1%$143.55M$5.65M-1.71180Positive News
Gap Up
ANIX
Anixa Biosciences
2.9063 of 5 stars
$4.31
-4.8%
$9.00
+109.1%
+36.2%$142.51M$210K-12.375News Coverage
High Trading Volume
ABOS
Acumen Pharmaceuticals
2.9478 of 5 stars
$2.30
+8.3%
$7.00
+205.0%
-29.0%$140.52MN/A-1.0220
BTMD
biote
2.1719 of 5 stars
$2.83
-1.0%
$6.00
+112.0%
-46.6%$140.41M$197.19M3.16194
TVGN
Tevogen Bio
2.6954 of 5 stars
$0.70
-1.6%
$10.00
+1,320.5%
-59.2%$138.68MN/A-3.713
ZYBT
Zhengye Biotechnology
N/A$2.88
+0.7%
N/AN/A$135.85M$25.53M0.00278
TIL
Instil Bio
3.0444 of 5 stars
$19.73
-3.2%
$88.50
+348.6%
-49.1%$133.75MN/A-1.53410Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:PLUR) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners